Completed PHASE4 INTERVENTIONAL 2-arm
NCT07075289
Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo
Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo: A Randomized Comparative Study on Inflammatory Markers, Quality of Life, and Symptom Resolution
Sponsor: Dexa Medica Group
Interventions
Betahistine Mesylate tablet DLBS1033
Updated 1 time since 2025 Last updated: Jul 10, 2025 Started: Apr 1, 2024 Primary completion: Aug 31, 2024 Completion: Dec 27, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07075289, this PHASE4 trial focuses on Benign Paroxysmal Positional Vertigo (Disorder) and remains completed. Sponsored by Dexa Medica Group, it has been updated 1 time since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Completed — PHASE4
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Dexa Medica Group
- Universitas Sebelas Maret
Data source: Universitas Sebelas Maret
For direct contact, visit the study record on ClinicalTrials.gov .